COR vs. ONC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at COR and ONC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
COR is a standard domestic listing, while ONC trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | COR | ONC |
|---|---|---|
| Company Name | Cencora, Inc. | BeOne Medicines Ltd. |
| Country | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 56.43 billion USD | 37.34 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | April 4, 1995 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of COR and ONC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | COR | ONC |
|---|---|---|
| 5-Day Price Return | 4.54% | -0.79% |
| 13-Week Price Return | 4.55% | 2.91% |
| 26-Week Price Return | 18.25% | 17.54% |
| 52-Week Price Return | 22.40% | 20.61% |
| Month-to-Date Return | 1.73% | -1.87% |
| Year-to-Date Return | 29.54% | 45.19% |
| 10-Day Avg. Volume | 1.53M | 3.15M |
| 3-Month Avg. Volume | 1.55M | 2.83M |
| 3-Month Volatility | 18.92% | 45.66% |
| Beta | 0.63 | 0.60 |
Profitability
Return on Equity (TTM)
COR
196.32%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
COR’s Return on Equity of 196.32% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
ONC
-12.94%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
ONC has a negative Return on Equity of -12.94%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
COR
0.60%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
Falling into the lower quartile for the Health Care Providers & Services industry, COR’s Net Profit Margin of 0.60% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
ONC
-10.58%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
ONC has a negative Net Profit Margin of -10.58%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
COR
0.85%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
COR’s Operating Profit Margin of 0.85% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
ONC
-7.30%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
ONC has a negative Operating Profit Margin of -7.30%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | COR | ONC |
|---|---|---|
| Return on Equity (TTM) | 196.32% | -12.94% |
| Return on Assets (TTM) | 2.70% | -7.59% |
| Net Profit Margin (TTM) | 0.60% | -10.58% |
| Operating Profit Margin (TTM) | 0.85% | -7.30% |
| Gross Profit Margin (TTM) | 3.40% | 84.66% |
Financial Strength
Current Ratio (MRQ)
COR
0.90
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
COR’s Current Ratio of 0.90 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
ONC
1.95
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
ONC’s Current Ratio of 1.95 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
COR
4.16
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
With a Debt-to-Equity Ratio of 4.16, COR operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
ONC
0.32
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
ONC’s Debt-to-Equity Ratio of 0.32 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
COR
13.67
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
COR’s Interest Coverage Ratio of 13.67 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
ONC
-132.16
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
ONC has a negative Interest Coverage Ratio of -132.16. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | COR | ONC |
|---|---|---|
| Current Ratio (MRQ) | 0.90 | 1.95 |
| Quick Ratio (MRQ) | 0.52 | 1.66 |
| Debt-to-Equity Ratio (MRQ) | 4.16 | 0.32 |
| Interest Coverage Ratio (TTM) | 13.67 | -132.16 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
COR
0.77%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Yield of 0.77% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
ONC
0.18%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC’s Dividend Yield of 0.18% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio (TTM)
COR
22.69%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Payout Ratio of 22.69% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
ONC
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | COR | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.77% | 0.18% |
| Dividend Payout Ratio (TTM) | 22.69% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
COR
29.60
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
COR’s P/E Ratio of 29.60 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ONC
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for ONC is currently unavailable.
Price-to-Sales Ratio (TTM)
COR
0.18
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, COR’s P/S Ratio of 0.18 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
ONC
8.38
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
ONC’s P/S Ratio of 8.38 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
COR
29.35
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
At 29.35, COR’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
ONC
8.99
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
ONC’s P/B Ratio of 8.99 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | COR | ONC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 29.60 | -- |
| Price-to-Sales Ratio (TTM) | 0.18 | 8.38 |
| Price-to-Book Ratio (MRQ) | 29.35 | 8.99 |
| Price-to-Free Cash Flow Ratio (TTM) | 8.78 | -- |